Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells

BACKGROUND: Development of resistance to targeted therapies has tempered initial optimism that precision oncology would improve poor outcomes for cancer patients. Resistance mechanisms, however, can also confer new resistance-specific vulnerabilities, termed collateral sensitivities. Here we investi...

Descripción completa

Detalles Bibliográficos
Autores principales: Berlak, Mareike, Tucker, Elizabeth, Dorel, Mathurin, Winkler, Annika, McGearey, Aleixandria, Rodriguez-Fos, Elias, da Costa, Barbara Martins, Barker, Karen, Fyle, Elicia, Calton, Elizabeth, Eising, Selma, Ober, Kim, Hughes, Deborah, Koutroumanidou, Eleni, Carter, Paul, Stankunaite, Reda, Proszek, Paula, Jain, Neha, Rosswog, Carolina, Dorado-Garcia, Heathcliff, Molenaar, Jan Jasper, Hubank, Mike, Barone, Giuseppe, Anderson, John, Lang, Peter, Deubzer, Hedwig Elisabeth, Künkele, Annette, Fischer, Matthias, Eggert, Angelika, Kloft, Charlotte, Henssen, Anton George, Boettcher, Michael, Hertwig, Falk, Blüthgen, Nils, Chesler, Louis, Schulte, Johannes Hubertus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185889/
https://www.ncbi.nlm.nih.gov/pubmed/35689207
http://dx.doi.org/10.1186/s12943-022-01583-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185889/
https://www.ncbi.nlm.nih.gov/pubmed/35689207
http://dx.doi.org/10.1186/s12943-022-01583-z

Ejemplares similares